Compare STRT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | FULC |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.3M | 285.4M |
| IPO Year | 1996 | 2019 |
| Metric | STRT | FULC |
|---|---|---|
| Price | $81.74 | $3.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $93.00 | $16.38 |
| AVG Volume (30 Days) | 73.5K | ★ 1.3M |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.53 | N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $20.63 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $57.01 | $2.83 |
| 52 Week High | $92.50 | $15.74 |
| Indicator | STRT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 51.01 |
| Support Level | $72.94 | $3.44 |
| Resistance Level | $84.46 | $3.96 |
| Average True Range (ATR) | 3.46 | 0.14 |
| MACD | -0.96 | 0.03 |
| Stochastic Oscillator | 10.84 | 73.86 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.